NICE Rejects Donanemab for NHS Use Due to Cost ...

By João L. Carapinha

October 24, 2024

The article from the National Institute for Health and Care Excellence (NICE) on the new Alzheimer’s treatment donanemab highlights several key points regarding the decision not to recommend this drug for use in the NHS. Essentially, donanemab has...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.